Robust carbon-ion optimization improves dose stability but does not always preserve LET
In a constrained phantom target, robust optimization reduced worst-case dose loss but increased minimum LET loss from 11.7% to 16.7%.
In a constrained phantom target, robust optimization reduced worst-case dose loss but increased minimum LET loss from 11.7% to 16.7%.
In 15 pelvic osteosarcoma plans, LET optimization reduced LEM-I versus mMKM target dose discrepancies by up to 9% of prescription, with modest robustness penalties.
In PACK, one-year survival reached 78% after carbon-ion chemoradiotherapy, but progression remained frequent and no randomized comparator was available.
Carbon-ion minibeams show preclinical tissue-sparing potential, but high-LET dosimetry, biological dose heterogeneity and organ motion remain major barriers to clinical translation.
Only 36 carbon-ion studies were open to enrollment worldwide, with most early-phase and 21 concentrated at three centers.
In 39 patients, carbon-ion RT achieved 91.2% two-year local control without grade ≥3 acute radiation-associated toxicity.
In eight previously irradiated patients, CIRT achieved 71% one-year local control and 75% survival, with grade ≥3 toxicity in 25%.
Carbon ions prolonged tumor-cell damage while chronic hypoxia supported late proliferative and macrophage rebound in rat prostate tumors.
Life-threatening bilateral pneumonitis with concurrent Pneumocystis infection developed three days after carbon-ion RT in a patient previously treated with nivolumab.
Multi-RBE carbon-ion optimization increased near-minimum GTV LET by 29.2% while maintaining conventional dose coverage and interfraction robustness.
Robust optimization improved target coverage with less lung-dose penalty than margin expansion, while density override was particularly useful for solid tumors.
Carbon-ion schedules produced similar tumour outcomes, but sacral insufficiency fractures occurred in 47% versus 24% with 4 Gy(RBE) fractions.
Different carbon-ion RBE models can assign substantially different biological doses to the same absorbed-dose distribution, requiring context-specific translation.
The Transformer calculated carbon-ion pencil-beam doses in 14 milliseconds with 98.0% gamma agreement at stringent 1%/1 mm criteria.
ATR inhibition increased radiation-induced cell killing and inflammatory signalling in KRAS wild-type pancreatic cancer cells, with weaker immunogenic effects in KRAS-mutated cells.